CD33 and neoplasm: Additionally, considering the transient but significant tumor response, the authors suggested that CAR.CD33 T-cells could be used as a ‘bridge’ to an allo-HSCT [14], thus rescuing possible off-target myelotoxic effects of the CAR.CD33 T-cells with the HSCT.